Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajko Reljic

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|May 26, 2007
IFN-gamma therapy of tuberculosis and related infectionsRajko Reljic
Immunology Letters|July 14, 2006
In search of the elusive mouse macrophage Fc-alpha receptorRajko Reljic
The Lancet. Infectious Diseases|November 25, 2006
A case for passive immunoprophylaxis against tuberculosisRajko Reljic, Juraj Ivanyi
Recent Patents on Anti-Infective Drug Discovery|June 13, 2009
Social leverage of intellectual property: road to the development of better therapy for tuberculosisHarry Thangaraj, Rajko Reljic
Frontiers in Immunology|December 3, 2019
Editorial: Nanoparticle Vaccines Against Infectious DiseasesRajko Reljic, África González-Fernández
Immunotherapy|October 24, 2014
Development of a new tuberculosis vaccine: is there value in the mucosal approach?Gil Reynolds Diogo, Rajko Reljic
Tuberculosis (Edinburgh, Scotland)|March 3, 2006
Mucosal immunotherapy of tuberculosis: is there a value in passive IgA?Rajko Reljic, Ann Williams, Juraj Ivanyi
Immunology Letters|May 12, 2004
Mouse monoclonal IgA binds to the galectin-3/Mac-2 lectin from mouse macrophage cell linesRajko Reljic, Carol Crawford, Stephen Challacombe, et al.
Immune Network|September 11, 2019
Emerging Themes for the Role of Antibodies in TuberculosisAndy C Tran, Mi-Young Kim, Rajko Reljic
International Immunology|March 25, 2004
Mouse IgA inhibits cell growth by stimulating tumor necrosis factor-alpha production and apoptosis of macrophage cell linesRajko Reljic, Carol Crawford, Stephen Challacombe, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|May 26, 2007
IFN-gamma therapy of tuberculosis and related infectionsRajko Reljic
Immunology Letters|July 14, 2006
In search of the elusive mouse macrophage Fc-alpha receptorRajko Reljic
The Lancet. Infectious Diseases|November 25, 2006
A case for passive immunoprophylaxis against tuberculosisRajko Reljic, Juraj Ivanyi
Recent Patents on Anti-Infective Drug Discovery|June 13, 2009
Social leverage of intellectual property: road to the development of better therapy for tuberculosisHarry Thangaraj, Rajko Reljic
Frontiers in Immunology|December 3, 2019
Editorial: Nanoparticle Vaccines Against Infectious DiseasesRajko Reljic, África González-Fernández
Immunotherapy|October 24, 2014
Development of a new tuberculosis vaccine: is there value in the mucosal approach?Gil Reynolds Diogo, Rajko Reljic
Tuberculosis (Edinburgh, Scotland)|March 3, 2006
Mucosal immunotherapy of tuberculosis: is there a value in passive IgA?Rajko Reljic, Ann Williams, Juraj Ivanyi
Immunology Letters|May 12, 2004
Mouse monoclonal IgA binds to the galectin-3/Mac-2 lectin from mouse macrophage cell linesRajko Reljic, Carol Crawford, Stephen Challacombe, et al.
Immune Network|September 11, 2019
Emerging Themes for the Role of Antibodies in TuberculosisAndy C Tran, Mi-Young Kim, Rajko Reljic
International Immunology|March 25, 2004
Mouse IgA inhibits cell growth by stimulating tumor necrosis factor-alpha production and apoptosis of macrophage cell linesRajko Reljic, Carol Crawford, Stephen Challacombe, et al.
Pageof 7